Subunit vaccines

vaccine against Hepatitis B

vaccine protecting against whooping cough

vaccine against COVID-19

thumb|A poster advertising trials of the RTS,S vaccine RTS,S/AS01 (trade name Mosquirix) is a recombinant protein-based malaria vaccine. It is one of two malaria vaccines approved (the other is R21/Matrix-M). , the vaccine has been given to 1million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production expands. 18 million doses have been allocated for 2023–2025. It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1–2 years. The vaccine reduces hospital ad

vaccine consisting of one or more antigens that stimulate a strong immune response

vaccine against respiratory syncytial virus (RSV)